Kayvan R. Keshari1, Renuka Sriram1, Mark Van Criekinge1, David M. Wilson1, Zhen J. Wang1, Daniel B. Vigneron1, Donna M. Peehl2, John Kurhanewicz1
1Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, United States; 2Stanford University, Stanford, CA, United States
The treatment of prostate cancer has been impeded by both the lack of clinically relevant disease models and biomarkers that track tumor progression. Hyperpolarized 13C MR has been developed to address these concerns, and safety of 13C pyruvate was confirmed in a recent clinical trial. The present study provides the first validation of HP lactate as a prostate cancer biomarker in human tissues, critical for the interpretation of in vivo studies. A prostate tissue slice culture model that recapitulates the metabolic profile of prostate cancer in vivo was developed, applied to a perfused cell (bioreactor) platform.